Myrtelle Inc.
BiotechnologyGene Therapy
New York, NY
2021
founded
About
Myrtelle Inc. is a clinical-stage gene therapy company carrying the mission of developing innovative treatments for neurodegenerative diseases that primarily affect myelin and white matter in the brain. With a particular focus on Canavan disease, the company addresses critical gaps in treatment options for rare genetic disorders of the central nervous system, aiming to improve patient outcomes significantly.
Company Values
Myrtelle stands out due to its advanced gene therapy approach utilizing proprietary adeno-associated virus (AAV) technology tailored to treat complex neurological disorders.